UBS AM’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.9K | Hold |
1,710
| – | – | ﹤0.01% | 3206 |
|
|
2026
Q1 | $10.9K | Buy |
+1,710
| New | +$11K | ﹤0.01% | 3290 |
|
|
2021
Q4 | – | Sell |
-42,211
| Closed | -$296K | – | 2890 |
|
|
2021
Q3 | $296K | Hold |
42,211
| – | – | ﹤0.01% | 2621 |
|
|
2021
Q2 | $387K | Buy |
42,211
+552
| +1% | +$5.59K | ﹤0.01% | 2598 |
|
|
2021
Q1 | $405K | Buy |
41,659
+7,121
| +21% | +$79.5K | ﹤0.01% | 2445 |
|
|
2020
Q4 | $354K | Buy |
34,538
+5,384
| +18% | +$54.5K | ﹤0.01% | 2385 |
|
|
2020
Q3 | $294K | Hold |
29,154
| – | – | ﹤0.01% | 2308 |
|
|
2020
Q2 | $304K | Sell |
29,154
-3,250
| -10% | -$33.6K | ﹤0.01% | 2277 |
|
|
2020
Q1 | $273K | Sell |
32,404
-728
| -2% | -$7.07K | ﹤0.01% | 2184 |
|
|
2019
Q4 | $290K | Buy |
33,132
+2,311
| +7% | +$19.1K | ﹤0.01% | 2376 |
|
|
2019
Q3 | $332K | Buy |
30,821
+5,165
| +20% | +$55.8K | ﹤0.01% | 2422 |
|
|
2019
Q2 | $326K | Buy |
25,656
+8,238
| +47% | +$190K | ﹤0.01% | 2381 |
|
|
2019
Q1 | $676K | Buy |
17,418
+7,157
| +70% | +$219K | ﹤0.01% | 1981 |
|
|
2018
Q4 | $209K | Sell |
10,261
-4,734
| -32% | -$142K | ﹤0.01% | 2378 |
|
|
2018
Q3 | $688K | Sell |
14,995
-4,261
| -22% | -$205K | ﹤0.01% | 1952 |
|
|
2018
Q2 | $1.14M | Sell |
19,256
-1,552
| -7% | -$89.9K | ﹤0.01% | 1766 |
|
|
2018
Q1 | $1.42M | Buy |
20,808
+2,408
| +13% | +$180K | ﹤0.01% | 1633 |
|
|
2017
Q4 | $1.82M | Buy |
18,400
+1,837
| +11% | +$206K | ﹤0.01% | 1475 |
|
|
2017
Q3 | $1.98M | Buy |
16,563
+1,115
| +7% | +$104K | ﹤0.01% | 1409 |
|
|
2017
Q2 | $1.35M | Buy |
15,448
+7,987
| +107% | +$447K | ﹤0.01% | 1529 |
|
|
2017
Q1 | $278K | Hold |
7,461
| – | – | ﹤0.01% | 2036 |
|
|
2016
Q4 | $229K | Sell |
7,461
-5,430
| -42% | -$235K | ﹤0.01% | 2058 |
|
|
2016
Q3 | $864K | Buy |
12,891
+300
| +2% | +$15.2K | ﹤0.01% | 1742 |
|
|
2016
Q2 | $375K | Hold |
12,591
| – | – | ﹤0.01% | 2114 |
|
|
2016
Q1 | $370K | Sell |
12,591
-6,515
| -34% | -$294K | ﹤0.01% | 2100 |
|
|
2015
Q4 | $1.5M | Sell |
19,106
-82,045
| -81% | -$6.44M | ﹤0.01% | 1574 |
|
|
2015
Q3 | $7.62M | Sell |
101,151
-1,959
| -2% | -$185K | 0.01% | 933 |
|
|
2015
Q2 | $12M | Sell |
103,110
-61,990
| -38% | -$11.2M | 0.01% | 839 |
|
|
2015
Q1 | $39M | Buy |
165,100
+3,800
| +2% | +$812K | 0.04% | 493 |
|
|
2014
Q4 | $30.5M | Buy |
161,300
+5,700
| +4% | +$1.26M | 0.03% | 585 |
|
|
2014
Q3 | $37.1M | Buy |
155,600
+8,200
| +6% | +$1.68M | 0.04% | 503 |
|
|
2014
Q2 | $9.73M | Buy |
+147,400
| New | +$10.5M | 0.01% | 859 |
|
Other funds holding PBYI
ACA
UBS AM's PBYI Position: Q2 2026 in Review
UBS AM held its Puma Biotechnology (PBYI) position steady in Q2 2026 at 1,710 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3206.
UBS AM first reported a position in PBYI in Q2 2014 and has held it in 32 quarters since. The position peaked at $39M in Q1 2015. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.
- UBS AM held 1,710 shares of Puma Biotechnology worth $13.9K as of Q2 2026.
- UBS AM left its Puma Biotechnology share count unchanged in Q2 2026.
- Puma Biotechnology made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3206 holding.
- UBS AM first reported a position in Puma Biotechnology in Q2 2014 and has held it in 32 quarters since.
- UBS AM's Puma Biotechnology position peaked at $39M in Q1 2015.
- 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.